



COLORADO

Department of Health Care
Policy & Financing

Drug Utilization Review Board MEETING AGENDA

May 10, 2022

Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at

<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

Health First Colorado, Colorado's Medicaid program

DUR Board Members	DUR Team
Alison Shmerling, MD, MPH (Chair)	Jeffrey Taylor, PharmD (HCPF)
Liza Wilson Claus, PharmD (Vice Chair)	Julia Rawlings, PharmD (CO-DUR)
Todd Brubaker, DO	Robert L Page II, PharmD, MSPH (CO DUR)
Brian Jackson, MD, MA	Gina Moore, PharmD, MBA (CO DUR)
Shilpa Klocke, PharmD	Heather Anderson, PhD (CO DUR)
Patricia Lanus, BSPHarm, MHA	Garth Wright, MPH (CO DUR)
	Vanessa Patterson, MPH (CO DUR)

1. Call to Order
2. Roll Call and Introductions
3. Virtual Meeting Information and General Announcements
4. Colorado Department of Health Care Policy and Financing Updates
5. Final Approval of Minutes from the February 8, 2022 Meeting
7. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

Presentations:

- Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at jeffrey.taylor@state.co.us
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting.

6. Clinical Updates and General Orders
 - FDA New Product & Safety Updates
 - Quarterly Module Summaries
 - Retrospective DUR Reports
 - Quarterly Drug Utilization Reports

Our mission is to improve health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>





COLORADO

Department of Health Care
Policy & Financing

8. New Business (open for public testimony and Board review)

Proposed Criteria for PDL Drug Classes Scheduled for Review

- Tetracyclines
- Angiotensin Modifiers
 - ACE Inhibitors, ARBs
- PAH Therapies
 - PDEIs, Endothelin Antagonists, Prostanoids & Guanylate Cyclase Stimulators
- Statins & Combinations
- Acne Agents, Topical
- Anti-Psoriatics
- Immunomodulators, Topical
 - Atopic Dermatitis, Antineoplastics & Other Agents
- Topical Steroids
 - Low, Medium, High & Very High Potency
- Antiemetics
- *H. pylori* Treatments
- Pancreatic Enzymes
- Anticoagulants
- Erythropoiesis Stimulating Agents
- Benign Prostatic Hyperplasia (BPH) Agents
- **Mass review drug classes***
 - Alpha-Blockers
 - Beta-Blockers - Single Agent, Anti-Arrhythmics & Combinations
 - Calcium Channel Blockers - DHPs & Non-DHPs
 - Angiotensin Modifiers - Renin Inhibitors & Combinations
 - Lipotropics - Bile Acid Sequestrants, Fibrates & Other Agents
 - Acne Agents, Oral Isotretinoin
 - Rosacea Agents
 - Androgenic Agents - Topical, Injectable & Oral
 - Bile Salts
 - GI Motility, Chronic
 - Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents
 - Proton Pump Inhibitors
 - Non-Biologic Ulcerative Colitis Agents
 - Anti-Platelets
 - Colony Stimulating Factors
 - Phosphate Binders

Our mission is to improve health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>





COLORADO

Department of Health Care Policy & Financing

** Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

9. Proposed Prior Authorization Criteria for Other Selected Products

- Besremi (ropeginterferon alfa-2b)
- Vyvgart (efgartigimod alfa)
- Leqvio (inclisiran)
- Adbry (tralokinumab-ldrm)
- Isturisa (osilodrostat)
- Recorlev (levoketoconazole)
- Dojolvi (triheptanoin)

10. Adjournment

Next meeting date
August 9, 2022
1:00 pm to 5:00 pm

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

